LQT-23 is a potent, highly differentiated, first-in-class allosteric small molecule inhibitor of MSH3/MutSβ Unique mechanism of action with potential to ...
LoQus23 Therapeutics, based at Granta Park in Cambridge, has stepped up its bid to combat Huntington’s Disease (HD). It has ...
InnoCare receives China NMPA approval to initiate phase II trial of TYK2 inhibitor ICP-488 for cutaneous lupus erythematosus: Beijing Wednesday, December 24, 2025, 18:00 Hrs [IST] ...
At the recent ELRIG Drug Discovery conference, Technology Networks<i/> spoke with Dr. Kundan Sharma to learn more about how cell-free expression platforms are transforming membrane protein research.
TipRanks on MSN
Sino Biopharm’s oral psoriasis drug TQH3906 delivers biologic-like efficacy in phase II trial
Sino Biopharmaceutical ( ($HK:1177) ) has provided an update. Sino Biopharmaceutical has reported positive Phase II clinical trial results for ...
Northwestern University scientists have uncovered a hidden molecular "control switch" inside a protein that helps the body ...
We have selected an allosteric ribozyme ligase from a random sequence population that is activated up to 10,000-fold by oligonucleotide effectors. The ribozyme conforms to a classic two-state model ...
Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback